Exacerbation Rate Reduction With Mepolizumab Stratified by Maintenance Oral Corticosteroids Use and Eosinophil Levels: A Post Hoc Analysis of the DREAM and MENSA Studies

J Investig Allergol Clin Immunol. 2022 Apr 19;32(2):148-150. doi: 10.18176/jiaci.0714. Epub 2021 Jun 4.

Authors

I Bobolea¹, D Bañas², C Melero³, A I de Andrés², S Joksaite², G Sánchez-Herrero²

Affiliations

¹ Allergy Section, Severe Asthma Unit. Department of Pulmonology and Allergy, Hospital Clinic Barcelona-Institute for Health Research (IdiBAPS), Barcelona, Spain.
² GSK, Madrid, Spain.
³ Hospital 12 de Octubre Institute for Health Research (i+12), Madrid, Spain.

PMID: 34085935
DOI: 10.18176/jiaci.0714

No abstract available

Keywords: Asthma; Eosinophils; Exacerbations; Mepolizumab; Oral corticosteroids (OCS).

Publication types

Comment

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Asthmatic Agents* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Eosinophils*
Humans

Substances

Adrenal Cortex Hormones
Anti-Asthmatic Agents
Antibodies, Monoclonal, Humanized
mepolizumab